Skip to main content

Perceptive Advisors — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

224
Companies
$26.6B
Total invested
$135.1M
Avg. check
14
Industries
Biotechnology 20Health Care 15Therapeutics 12Pharmaceutical 10Medical 9Life Science 5+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 224
Kindbody
May 2023

Kindbody is a fertility clinic network and family-building benefits provider for employers.

Employee Benefits · New York$25.0M Venture - Series Unknown
Acrivon Therapeutics
April 2024

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

Biotechnology · Cambridge$130.0M Post-IPO Equity
Forte Biosciences
April 2026

Forte Biosciences is a biotechnology company that focuses on dermatology.

Biotechnology · Sherman Oaks$150.0M Post-IPO Equity
Merida Biosciences
April 2025

Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.

Biotechnology · Cambridge$121.0M Series A
Opus Genetics(formerly Ocuphire Pharma)
April 2026

Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

Biopharma · Farmington Hills$35.0M Post-IPO Debt
Oncorus
April 2022

Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.

Biotechnology · Cambridge$20.0M Post-IPO Debt
Surf Bio
April 2024

Surf Bio develops therapeutic solutions for diabetes, oncology, infectious diseases, and gene therapy.

Biotechnology · Palo Alto$1.6M Grant
Oruka Therapeutics
April 2026

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$700.4M Post-IPO Equity
Endeavor BioMedicines
April 2024

Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.

Biotechnology · Solana Beach$132.5M Series C
Outlook Therapeutics
April 2026

Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.

Biopharma · Iselin$5.0M Post-IPO Equity
MeiraGTx
April 2026

MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.

Biotechnology · New York$100.0M Post-IPO Equity
Allogene Therapeutics
April 2026

Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.

Biotechnology · South San Francisco$200.4M Post-IPO Equity
Spyre Therapeutics
April 2026

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

Biotechnology · Sunrise$403.0M Post-IPO Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post-IPO Equity
Sionna Therapeutics
March 2024

Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).

Biotechnology · Natick$182.0M Series C
Orchard Therapeutics
March 2023

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

Biotechnology · London$34.0M Post-IPO Equity
Akero Therapeutics
March 2024

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Biotechnology · Cambridge$366.9M Post-IPO Equity
Zenas BioPharma
March 2026

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

Biopharma · Waltham$100.0M Post-IPO Equity
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post-IPO Equity
Emulate
March 2024

Emulate creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Biotechnology · Boston$47.1M Series F
Capstan Therapeutics
March 2024

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.

Biotechnology · San Diego$175.0M Series B
Hyperfine
March 2026

Hyperfine makes MRI accessible to every patient regardless of income or resources.

Computer · Guilford$40.0M Post-IPO Debt
Inhibrx
March 2026

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Biopharma · La Jolla$75.0M Post-IPO Debt
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note

Where Perceptive Advisors invests

Biotechnology20
Health Care15
Therapeutics12
Pharmaceutical10
Medical9
Life Science5

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?

Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?

Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 14 different industry categories.

What is Perceptive Advisors's largest investment?

Among tracked funding rounds, Oruka Therapeutics received $700.4M in a Post-IPO Equity round. Perceptive Advisors's total known invested capital is $26.6B.

What is the average investment size for Perceptive Advisors?

Perceptive Advisors's average investment size is $135.1M across its portfolio of 224 companies.

What are Perceptive Advisors's most recent investments?

Recent Perceptive Advisors portfolio additions include Kindbody, Acrivon Therapeutics, Forte Biosciences, Merida Biosciences, Opus Genetics(formerly Ocuphire Pharma). These companies were founded in 2020 or later.

Reach the founders behind these 224 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →